Systemic Mastocytosis clinical trials

Explore recruiting systemic mastocytosis clinical trials.

Recruiting systemic mastocytosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Systemic Mastocytosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis

Netherlands, Czechia, France, Spain, Norway, Poland +6 more

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study

Italy, Netherlands, Belgium, Norway, Sweden

Therapeutic use (Phase IV) EU CTIS Study details

The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Portugal, Denmark, Sweden, France, Spain, Germany +9 more

Phase II and Phase III (Integrated) EU CTIS Study details

A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU 285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy

France, Netherlands, Denmark, Sweden, Germany, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies

Belgium, Spain, France, Netherlands, Norway, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Systemic Mastocytosis trials by city

Systemic Mastocytosis in Toronto Systemic Mastocytosis in Vancouver Systemic Mastocytosis in Montreal Systemic Mastocytosis in Calgary Systemic Mastocytosis in Edmonton Systemic Mastocytosis in Ottawa Systemic Mastocytosis in Winnipeg Systemic Mastocytosis in Quebec City Systemic Mastocytosis in Hamilton Systemic Mastocytosis in Kitchener Systemic Mastocytosis in London Systemic Mastocytosis in Halifax Systemic Mastocytosis in New York Systemic Mastocytosis in Los Angeles Systemic Mastocytosis in Chicago Systemic Mastocytosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease